Antiseizure Medication Taper Protocols in the Epilepsy Monitoring Unit

The Epilepsy Monitoring Unit (EMU) faces a built-in tension that every epileptologist knows: scalp video-EEG monitoring requires patients to have seizures, yet the medications being evaluated exist to prevent them. A new article in Neurology®, the journal of the American Academy of Neurology, takes up the question of how to optimize antiseizure medication (ASM) taper during inpatient monitoring — one of the most consequential routine decisions in clinical neurophysiology practice.

The piece, titled "Optimizing Antiseizure Medication Taper in the Epilepsy Monitoring Unit," addresses a problem reading-room and monitoring-unit teams confront daily. When patients admitted for scalp video-EEG with typical seizure semiology reduce or discontinue their ASMs, clinicians must weigh the diagnostic yield of capturing habitual events against the risk of seizure clusters, status epilepticus, and other adverse outcomes. Taper too slowly, and the admission ends without the ictal recordings needed to localize the epileptogenic zone or classify the epilepsy. Taper too aggressively, and the patient may suffer harm that outweighs the diagnostic benefit.

This trade-off is not hypothetical. EMU admissions are among the few inpatient settings where provoking seizures is part of the protocol, and the taper strategy directly shapes both the probability of recording an event and the severity of what gets provoked. The article examines the variables that inform that calculation: which medications to reduce first, how quickly to reduce them, and how patient-specific factors — seizure frequency before admission, seizure type, and medication load — should modulate the approach.

For EEG technologists and clinical neurophysiologists, the practical stakes are clear. The speed of the ASM taper determines the temporal window during which technologists must maintain vigilance at the bedside, respond rapidly to seizure onset, and ensure that ictal EEG is captured with adequate montage coverage and video correlation. A seizure that arrives before the team is prepared, or a cluster that escalates faster than rescue medications can be administered, converts a diagnostic admission into an emergency.

The article also speaks to a recurring quality-and-safety theme in EMU practice: standardization. Taper practice varies considerably across monitoring units, and the piece situates that variability within the broader effort to define evidence-based EMU protocols. Where evidence remains thin — as it often does for taper timing and medication selection — the authors' discussion offers a framework for units looking to formalize their own procedures rather than relying on individual physician preference alone.

Notably, the subject sits at the intersection of diagnostic yield and pharmacovigilance. Unlike ambulatory EEG, where medication is typically held constant, the EMU deliberately engineers a period of elevated seizure susceptibility. That makes ASM taper one of the few areas of routine EEG practice where a pharmacologic intervention is a component of the recording protocol itself, and where the neurophysiology team, the nursing staff, and the epileptologist share responsibility for the safety margin.

The Neurology® article arrives as EMUs continue to see rising demand for presurgical evaluation, in which ictal scalp EEG recordings — and, for many patients, subsequent intracranial monitoring — depend on successful seizure capture during a finite admission window. A well-designed taper protocol can shorten time to first seizure, reduce length of stay, and improve the odds that a single admission yields the data needed for surgical candidacy decisions.

The piece contributes to an ongoing conversation in the field about how much provocation is enough — and how much is too much. Readers working in epilepsy monitoring can expect the discussion to inform local protocol reviews, particularly at units that have not yet formalized taper guidelines. Future studies, the article's framing suggests, will need to link specific taper strategies to concrete outcomes — seizure capture rates, adverse event rates, and admission duration — before consensus recommendations can move from expert opinion to standard of care.